Rapid response of recalcitrant linear IgA bullous dermatosis to omalizumab: A case report and literature review

Dermatol Ther. 2022 Dec;35(12):e15920. doi: 10.1111/dth.15920. Epub 2022 Oct 27.

Authors

Xin Tong^{1

2

3}, Long Geng^{1

2

3}, Xing-Hua Gao^{1

2

3}, Hong-Hui Xu^{1

2

3}

Affiliations

¹ Department of Dermatology, The First Hospital of China Medical University, Shenyang, China.
² National Health Commission Key Laboratory of Immunodermatology, Shenyang, China.
³ Key Laboratory of Immunodermatology of Ministry of Education, Shenyang, China.

PMID: 36219536
DOI: 10.1111/dth.15920

No abstract available

Publication types

Review
Case Reports
Letter

MeSH terms

Humans
Immunoglobulin A
Linear IgA Bullous Dermatosis* / diagnosis
Linear IgA Bullous Dermatosis* / drug therapy
Omalizumab / therapeutic use
Pemphigoid, Bullous*

Substances

Omalizumab
Immunoglobulin A